1. Home
  2. RYTM vs NNI Comparison

RYTM vs NNI Comparison

Compare RYTM & NNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • NNI
  • Stock Information
  • Founded
  • RYTM 2008
  • NNI 1978
  • Country
  • RYTM United States
  • NNI United States
  • Employees
  • RYTM N/A
  • NNI N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • NNI Finance: Consumer Services
  • Sector
  • RYTM Health Care
  • NNI Finance
  • Exchange
  • RYTM Nasdaq
  • NNI Nasdaq
  • Market Cap
  • RYTM 3.8B
  • NNI 4.0B
  • IPO Year
  • RYTM 2017
  • NNI 2003
  • Fundamental
  • Price
  • RYTM $61.74
  • NNI $104.78
  • Analyst Decision
  • RYTM Strong Buy
  • NNI Hold
  • Analyst Count
  • RYTM 12
  • NNI 1
  • Target Price
  • RYTM $74.92
  • NNI $98.00
  • AVG Volume (30 Days)
  • RYTM 940.6K
  • NNI 62.1K
  • Earning Date
  • RYTM 05-06-2025
  • NNI 05-08-2025
  • Dividend Yield
  • RYTM N/A
  • NNI 1.07%
  • EPS Growth
  • RYTM N/A
  • NNI 109.22
  • EPS
  • RYTM N/A
  • NNI 5.02
  • Revenue
  • RYTM $130,126,000.00
  • NNI $1,354,961,000.00
  • Revenue This Year
  • RYTM $43.84
  • NNI $11.81
  • Revenue Next Year
  • RYTM $65.62
  • NNI $4.36
  • P/E Ratio
  • RYTM N/A
  • NNI $20.87
  • Revenue Growth
  • RYTM 68.06
  • NNI 15.70
  • 52 Week Low
  • RYTM $35.17
  • NNI $93.59
  • 52 Week High
  • RYTM $68.58
  • NNI $127.32
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 61.94
  • NNI 40.70
  • Support Level
  • RYTM $59.54
  • NNI $100.00
  • Resistance Level
  • RYTM $62.83
  • NNI $106.82
  • Average True Range (ATR)
  • RYTM 4.27
  • NNI 3.37
  • MACD
  • RYTM 1.00
  • NNI -0.06
  • Stochastic Oscillator
  • RYTM 92.04
  • NNI 48.39

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About NNI Nelnet Inc.

Nelnet Inc is a United States based company engaged in these four reportable segments; Loan Servicing and Systems focuses on student and consumer loan origination services and servicing, loan origination and servicing-related technology solutions, and outsourcing business services; Education Technology Services and Payments segment provides education services, payment technology, and community management solutions for K-12 schools, institutions, churches, and businesses; Asset Generation and Management segment includes the acquisition and management of student and other loan assets; and Nelnet Bank focuses on the private education and unsecured consumer loan markets. Maximum revenue for the company is generated from its Education Technology Services and Payments segment.

Share on Social Networks: